Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

Discovery of Novel CARs for Solid Tumors Using Senti REVEAL™

Wednesday, May 15, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Senti Biosciences has announced the discovery of novel CARs aimed at treating solid tumors using their Gene Circuit Technology Platform. This innovative approach may enhance the effectiveness of cancer therapies. The findings were presented at the ASGCT Annual Meeting, highlighting the company's commitment to advancing cancer treatment options.
Price reaction · baseline $3.71 (2024-05-15T13:36:00.000Z) · hit during market hours · 2 other SNTI headline(s) in the window, move may be shared
day 0 close · peak
+1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Discovery of novel CARs for treating solid tumors.
  • Utilization of advanced Gene Circuit Technology Platform.
  • Potential for significant advancements in cancer treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

• About Overview Team Board of Directors Scientific Advisory Board
• Approach Overview Gene Circuit Technology Platform
• Research & Pipeline Pipeline SENTI-202 for Acute Myeloid Leukemia Presentations & Publications Expanded Access to Investigational Medicines
• Investors Overview Press Releases Events and Presentations Analyst Coverage Financials and Filings Corporate Governance Documents and Charters Leadership Team Board of Directors Committee Composition Stock Information Investor Resources FAQ Email Alerts Contact Us
• Careers
• Overview
• Team
• Board of Directors
• Scientific Advisory Board
• Overview
• Gene Circuit Technology Platform
• Pipeline
• SENTI-202 for Acute Myeloid Leukemia
• Presentations & Publications
• Expanded Access to Investigational Medicines
• Overview
• Press Releases
• Events and Presentations
• Analyst Coverage
• Financials and Filings
• Corporate Governance Documents and Charters Leadership Team Board of Directors Committee Composition
• Stock Information
• Investor Resources FAQ Email Alerts Contact Us
• Documents and Charters
• Leadership Team
• Board of Directors
• Committee Composition
• FAQ
• Email Alerts
• Contact Us
ASGCT Annual Meeting Nick Frankel, PhD

View PDF

Frequently Asked Questions

What are the novel CARs discovered by Senti?

Senti Biosciences has developed novel CARs targeting solid tumors.

What technology does Senti use for CAR development?

Senti utilizes their Gene Circuit Technology Platform for CAR development.

Where were the findings presented?

The findings were presented at the ASGCT Annual Meeting.

What is the significance of these CARs?

These CARs may enhance the effectiveness of treatments for solid tumors.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare Senti Biosciences CAR therapy solid tumors Gene Circuit Technology ASGCT Annual Meeting
Last updated: May 15, 2024

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →